efavirenz and Malignant Melanoma

efavirenz has been researched along with Malignant Melanoma in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bartolini, S; Castellano, S; Cirilli, R; Lavia, P; Mai, A; Milite, C; Orlando, S; Rotili, D; Santoriello, M; Sbardella, G; Sciamanna, I; Serafino, A; Spadafora, C	1
Fais, S; Federici, C; Iessi, E; Lugini, L; Sciamanna, I; Spugnini, EP	1

Other Studies

2 other study(ies) available for efavirenz and Malignant Melanoma

Article	Year
Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors. Journal of medicinal chemistry, 2011, Aug-25, Volume: 54, Issue:16 Topics: Animals; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Fluorescent Antibody Technique, Indirect; Humans; Melanoma; Mice; Mice, Nude; Microscopy, Confocal; Molecular Structure; Pyrimidinones; Reverse Transcriptase Inhibitors; Tumor Burden; Xenograft Model Antitumor Assays	2011
Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase. Oncotarget, 2017, Jan-17, Volume: 8, Issue:3 Topics: Alkynes; Antineoplastic Combined Chemotherapy Protocols; Benzoxazines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclopropanes; Drug Evaluation, Preclinical; Drug Synergism; Humans; Lansoprazole; Melanoma; Proton Pump Inhibitors; Reverse Transcriptase Inhibitors; Spheroids, Cellular; Tumor Microenvironment	2017

Article

Year

Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors.

Journal of medicinal chemistry, 2011, Aug-25, Volume: 54, Issue:16

Topics: Animals; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Fluorescent Antibody Technique, Indirect; Humans; Melanoma; Mice; Mice, Nude; Microscopy, Confocal; Molecular Structure; Pyrimidinones; Reverse Transcriptase Inhibitors; Tumor Burden; Xenograft Model Antitumor Assays

2011

Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase.

Oncotarget, 2017, Jan-17, Volume: 8, Issue:3

Topics: Alkynes; Antineoplastic Combined Chemotherapy Protocols; Benzoxazines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclopropanes; Drug Evaluation, Preclinical; Drug Synergism; Humans; Lansoprazole; Melanoma; Proton Pump Inhibitors; Reverse Transcriptase Inhibitors; Spheroids, Cellular; Tumor Microenvironment

2017